“The combination of HeartBeat.bio’s proprietary Cardioid technology and Molecular Devices’ automated 3D cell culture and image analysis solutions, defines a powerful and compelling partnership. Together, we are committed to develop and commercialize the world’s first integrated, end-to-end high-throughput human cardiac organoid screening platform,” said Michael Krebs, CEO of HeartBeat.bio. “The collaboration establishes the foundation for HeartBeat.bio’s strategy to apply this unique 3D biology platform for cardiac drug development partnerships with pharma and proprietary discovery programs in heart failure.”
In addition to its role in cardiac diseases research, the application for cardiac safety is of great importance as cardiovascular safety concerns remain a leading cause of failure in clinical trials, which can be attributed in part to reliance on models that are limited in predictivity. The Molecular Devices platform built around HeartBeat.bio’s Cardioid technology is expected to improve preclinical research, leading to higher clinical trial success rates along with reduced costs and time for compound development.
“By collaborating with HeartBeat.bio, we’ll equip more researchers with the physiologically-relevant cell models, automated bioimaging technology, and reproducible workflows needed to drive development of novel heart disease treatments and reduce cardiovascular safety risk of drugs entering clinical trials,” said Susan Murphy, President of Molecular Devices. “Our ultimate goal is to help unleash the full potential of organoid research so that scientists are empowered to bring safer and more effective therapeutics to patients faster.”
With a leading pharmaceutical company already identified to help validate the offering for cardiac drug safety, the companies are open for additional customers to test and assess the predictive value of the platform as compared to today’s existing drug development methods.
“As Cardioids represent better predictive models than cardiomyocytes or engineered spheroid models, this collaboration has the potential to considerably improve preclinical drug profiling and significantly increase the efficiency of pharmaceutical drug development,” Murphy concluded.
To learn more about how HeartBeat.bio and Molecular Devices technologies are helping advance drug discovery, listen to this recorded panel discussion hosted by Drug Target Review.
HeartBeat.bio AG is dedicated to developing the first high-throughput human organoid screening platform for cardiac drug discovery. The technology platform is built on self-organizing, highly scalable cardiac organoids which recapitulate the human heart physiology and enable modeling of diseases such as drug-induced and genetic cardiomyopathies as well as myocardial infarction, heart remodeling and regeneration. HeartBeat.bio AG was founded in 2021 based on technology from the Institute of Molecular Biotechnology (IMBA) by a seasoned team with in-depth experience in organoid research, drug discovery and business development. The Company is located at the Vienna BioCenter in Austria. For further information, visit www.heartbeat.bio.
About Molecular Devices
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. Visit Molecular Devices at www.moleculardevices.com.
For Press Enquiries:
MC Services AG
Julia von Hummel, Andreas Jungfer
Phone: +49 89 210 228-0
Phone: +44 20 71485998